Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) - report of clinical outcomes at the recommended phase 2 dose (RP2D)

Blood (2025) 146 (Supplement 1): 1042.

https://doi.org/10.1182/blood-2025-1042

Published: 2025

Journal Articles

A Phase I, open-label study of CTD402, a universal CD7-targeting CAR T-cell therapy, in patients with relapsed/refractory severe aplastic anemia

Lele Zhang, Ruonan Li, Jing Zhang, Jianping Li, Neng Nie, Xingxin Li, Xiao Yu, Zhexiang Kuang, Liyun Li, Jingyu Zhao, Maria del Rosario, Xiao Shi, Yong Yu, Yali Zhou, Ming Gao, Wengang Ge, Jiangtao Ren, Jan Davidson-Moncada, Jun Shi

Blood (2025) 146 (Supplement 1): 3210.

https://doi.org/10.1182/blood-2025-3210

Published: 2025

Journal Articles

A single-arm, open-label, multi-center, phase 1b/2 Study to evaluate the safety, efficacy, and cellular pharmacokinetic profile of CTD402 in participants with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL) (TENACITY-01)

Blood (2025) 146 (Supplement 1): 5954.

https://doi.org/10.1182/blood-2025-5954

Published: 2025

Journal Articles

CD7-targeted universal CAR T-cell therapy in relapsed or refractory (R/R) acute myeloid leukemia (AML): Clinical results from CTD401/402 studies

Yong-xian Hu, Xiaoyu Zhu, Heng Mei, Ying Wang, Yali Zhou, Kangqi Bian, Maria del Rosario, Eileen McNulty, Ming Gao, Lu Han, Wengang Ge, Jan Davidson-Moncada, Jiangtao Ren, He Huang

Blood (2025) 146 (Supplement 1): 816.

https://doi.org/10.1182/blood-2025-816

Published: 2025

Journal Articles

Target enrichment long-range sequencing (TLES) reveals structural variations missed by PEM-seq

Shuhui Yu, Yueqiang Wang, Wenxin Zhu, Qin Chen, Biao Wang, Qiang Wu, Yali Zhou, Ling Yuan, Sha Li, Xiaojing Zhang, Mingxi Chen, Mengyao Wang, Liping Zhu, Yajin Ni, Jan Davidson-Moncada, Jiangtao Ren

Blood (2025) 146 (Supplement 1): 4122.

https://doi.org/10.1182/blood-2025-4122

Published: 2025

Journal Articles

CTD402: Allogeneic CAR-t manufacturing that overcomes donor- & process-derived variation with robust clinical activity

Xiaojing Zhang, Liping Zhu, Mengyao Wang, Shuhui Yu, Yu Liu, Mingxi Chen, Yanbo Liu, Yong Yu, Maria del Rosario, Wengang Ge, Jan Davidson-Moncada, Yajin Ni, Jiangtao Ren

Blood (2025) 146 (Supplement 1): 4180.

https://doi.org/10.1182/blood-2025-4180

Published: 2025

Journal Articles

CTA311, a universal anti-CD19 CAR t-cell therapy with improved persistence for patients with CD19+ relapsed/ refractory (R/R) b-cell acute lymphoblastic leukemia (B-ALL)

Guangyu Sun, Heng Mei, Anyou Wang, Tianzhong Pan, Yali Zhou, Gong Chen, Jiuqin Zeng, Kangqi Bian, Jan Davidson-Moncada, Bo Pei, Lu Han, Jiangtao Ren, Xiaoyu Zhu

Blood (2025) 146 (Supplement 1): 5920.

https://doi.org/10.1182/blood-2025-5920

Published: 2025

Journal Articles

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies

Blood (2025) 146 (10): 1163–1173.

https://doi.org/10.1182/blood.2025028387

Published: 2025

Includes: Supplemental data

Journal Articles

Adoptively Infused Memory-like Natural Killer Cells Impact Adaptive Immune Responses in Patients with Acute Myeloid Leukemia

Sergio Rutella, Jayakumar Vadakekolathu, Amanda F Cashen, Nitin Mahajan, Yanira Ruiz-Heredia, Alejandro Martín-Muñoz, Santiago Barrio, Melissa M Berrien-Elliott, Jan Davidson-Moncada, Todd A Fehniger

Blood (2023) 142 (Supplement 1): 4813.

https://doi.org/10.1182/blood-2023-184986

Published: 2023

Journal Articles

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Naturally Overcomes Tumor Microenvironment (TME) Metabolic Challenges, Retaining Anti-Tumor Potency

Nupur Bhatnagar, Vincent Petit, Jayakumar Vadakekolathu, Christian Pinset, Nitin Mahajan, John Dean, Christine Spingola, Laura Arthur, David Boocock, Clare Coveney, John Muth, Jan Baughman, Melissa M Berrien-Elliott, Marc Sitbon, Matthew L. Cooper, Jan Davidson-Moncada, Todd A Fehniger, Sergio Rutella

Blood (2023) 142 (Supplement 1): 4834.

https://doi.org/10.1182/blood-2023-178868

Published: 2023

Journal Articles

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Intrinsically Overcomes Factors Restricting Adoptive Cell Therapy (ACT) in Acute Myeloid Leukemia (AML)

Blood (2023) 142 (Supplement 1): 466.

https://doi.org/10.1182/blood-2023-184923

Published: 2023

Journal Articles

Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL)

Armin Ghobadi, Ibrahim Aldoss, Shannon L. Maude, Deepa Bhojwani, Alan S. Wayne, Ashish Bajel, Rawan Faramand, Ryan J Mattison, Bhagirathbhai Dholaria, Michael P. Rettig, Ken Jacobs, Ouiam Bakkacha, John Muth, Angela Pannunzio, Brett Ramsey, Eileen McNulty, Matt L. Cooper, Jan Davidson-Moncada, John F. DiPersio

Blood (2023) 142 (Supplement 1): 770.

https://doi.org/10.1182/blood-2023-178723

Published: 2023

Journal Articles

Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Blood (2017) 130 (Supplement 1): 637.

https://doi.org/10.1182/blood.V130.Suppl_1.637.637

Published: 2017

Journal Articles

Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies

Michael P Rettig, PhD, John Godwin, MD, Norbert Vey, Bernard Fox, PhD, Carmen Ballesteros-Merino, PhD, Carlo B Bifulco, MD, Daner Li, MS, Daniel Primo, PhD, Joan Ballesteros, PhD, Jichao Sun, PhD, Helene Lelièvre, PhD PharmD, Jan Baughman, MPH, Ross La Motte-Mohs, PhD, John Muth, MS, Paul Moore, PhD, Ezio Bonvini, MD, Jon Wigginton, John F DiPersio, MD PhD, Jan Davidson-Moncada, MDPhD

Blood (2017) 130 (Supplement 1): 1365.

https://doi.org/10.1182/blood.V130.Suppl_1.1365.1365

Published: 2017

Journal Articles

A Novel Method to Study the in Vivo Trafficking and Homing of Adoptively Transferred NK Cells in Rhesus Macaques and Humans

Jan Davidson-Moncada, MD PhD MSc, Noriko Sato, MD PhD, Robert F Hoyt, DVM, Robert N Reger, Marvin Thomas, DVM, MS, Randy Clevenger, Mark E. Metzger, Robert E. Donahue, Philip C Eclarinal, BS, CNMT, Lawrence Szajek, Gary L Griffiths, PhD, Cynthia E. Dunbar, MD, Peter Choyke, MD, Richard Childs, MD

Blood (2014) 124 (21): 659.

https://doi.org/10.1182/blood.V124.21.659.659

Published: 2014

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) - report of clinical outcomes at the recommended phase 2 dose (RP2D)

A Phase I, open-label study of CTD402, a universal CD7-targeting CAR T-cell therapy, in patients with relapsed/refractory severe aplastic anemia

A single-arm, open-label, multi-center, phase 1b/2 Study to evaluate the safety, efficacy, and cellular pharmacokinetic profile of CTD402 in participants with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL) (TENACITY-01)

CD7-targeted universal CAR T-cell therapy in relapsed or refractory (R/R) acute myeloid leukemia (AML): Clinical results from CTD401/402 studies

Target enrichment long-range sequencing (TLES) reveals structural variations missed by PEM-seq

CTD402: Allogeneic CAR-t manufacturing that overcomes donor- & process-derived variation with robust clinical activity

CTA311, a universal anti-CD19 CAR t-cell therapy with improved persistence for patients with CD19+ relapsed/ refractory (R/R) b-cell acute lymphoblastic leukemia (B-ALL)

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies

Adoptively Infused Memory-like Natural Killer Cells Impact Adaptive Immune Responses in Patients with Acute Myeloid Leukemia

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Naturally Overcomes Tumor Microenvironment (TME) Metabolic Challenges, Retaining Anti-Tumor Potency

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Intrinsically Overcomes Factors Restricting Adoptive Cell Therapy (ACT) in Acute Myeloid Leukemia (AML)

Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL)

Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies

A Novel Method to Study the in Vivo Trafficking and Homing of Adoptively Transferred NK Cells in Rhesus Macaques and Humans

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only